Last reviewed · How we verify
M923
M923 is a monoclonal antibody that targets and modulates IgG glycosylation to enhance immune function.
M923 is a monoclonal antibody that targets and modulates IgG glycosylation to enhance immune function. Used for Autoimmune and inflammatory diseases (Phase 3 development).
At a glance
| Generic name | M923 |
|---|---|
| Also known as | Adalimumab |
| Sponsor | Momenta Pharmaceuticals, Inc. |
| Drug class | Monoclonal antibody (glycoengineered) |
| Target | IgG Fc glycosylation / Fc receptors |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
M923 works by binding to and modifying the glycan structures on the Fc region of IgG antibodies, which enhances their ability to engage Fc receptors on immune cells. This glycoengineering approach aims to improve the effector functions of endogenous IgG antibodies, potentially enhancing immune responses against disease targets. The mechanism leverages Momenta's expertise in glycoprotein engineering to optimize antibody-mediated immunity.
Approved indications
- Autoimmune and inflammatory diseases (Phase 3 development)
Common side effects
Key clinical trials
- Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects (PHASE1)
- Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis (PHASE3)
- Usability of an AI for M923 in Subjects With Moderate to Severe RA (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M923 CI brief — competitive landscape report
- M923 updates RSS · CI watch RSS
- Momenta Pharmaceuticals, Inc. portfolio CI